Tesamorelin in HIV: the trial that defined a narrow indication

Tesamorelin is a synthetic growth hormone-releasing factor analogue with an N-terminal modification meant to extend its half-life relative to native GHRH. The trial that made it a medicine was specific. In the 2007 New England Journal of Medicine paper, Falutz and colleagues enrolled adults with HIV and excess abdominal fat and randomized them to tesamorelin or placebo for 26 weeks. Visceral adipose tissue, measured by CT, was the point of the study. The program later supported FDA approval of Egrifta for reduction of excess abdominal fat in HIV-associated lipodystrophy.

What improved, and what the indication is not

A pooled analysis of the two phase 3 trials, published in the Journal of Clinical Endocrinology & Metabolism in 2010, reported a reduction in visceral fat on the order of 15 percent, with little change in abdominal subcutaneous fat, plus improvements in triglycerides and patient-reported belly appearance. IGF-I rose, as a GHRH analogue would be expected to do. Glucose measures did not show a large mean split in that pooled look, which is not the same thing as “no metabolic risk in every patient.” The label is the constraint. Approval for HIV-associated lipodystrophy is not approval for athletic body composition, and it is not approval for a research vial that was never the Egrifta lot.

Why this paper is a useful review

It shows what a real peptide approval looks like: a named population, an imaging endpoint, a sponsor, and a label. Most peptides in consumer circulation do not have that stack. Tesamorelin does, and the stack is narrower than the marketing around “GH peptides” implies.